PBH Stock Forecast & Price Target

Prestige Consumer Healthcare has demonstrated strong financial resilience, with an increased estimate of EBITDA by approximately $15 million for 2026 and 2027, driven by higher anticipated sales growth. The company's forecasts indicate a revenue target of $7,322 million for the current fiscal period, reflecting a robust 13.2% growth, alongside an adjusted EBITDA projected to rise by 16.3% to $690 million, supported by a slight margin improvement. Moreover, management anticipates an acceleration in organic volume growth in the latter half of the fiscal year, bolstered by significant new product launches, positioning the company for continued financial strength.

Prestige Consumer Healthcare is facing significant challenges that contribute to a negative outlook on its stock. The company has reported a decline in adjusted EBITDA margins, with a 38 basis points year-over-year decrease attributed primarily to raw material cost inflation and the adverse effects of recent acquisitions, which are expected to yield lower margins in the near term. Additionally, ongoing input cost inflation and sluggish revenue growth raise concerns about future profitability, suggesting that further EBITDA margin compression and valuation multiple declines are likely.